25CN-NBOMe

25CN-NBOMe is a psychedelic drug and research chemical that was first synthesized in 2014 by a team at the University of Copenhagen. It is part of the NBOMe series of psychedelic phenethylamines, specifically a derivative of the 2C family of psychedelics.

Chemistry

25CN-NBOMe is a phenethylamine, which is a large family of psychoactive drugs and neurotransmitters such as dopamine and serotonin. It is a derivative of the 2C family of psychedelics which were first synthesized by Alexander Shulgin. The NBOMe series of drugs are analogs of the 2C family, but with a methoxybenzyl (NBOMe) group attached to the nitrogen of the phenethylamine backbone. This makes them much more potent than their 2C counterparts.

Pharmacology

The pharmacology of 25CN-NBOMe is not fully understood. It is known to act as a highly potent partial agonist for the 5-HT2A receptor, which is thought to be the primary target of the psychedelic effects of this compound. The NBOMe series of drugs are known for their high potency, with active doses in the microgram range.

Effects

The effects of 25CN-NBOMe can vary greatly depending on the dose, set and setting. They can include visual hallucinations, changes in perception, euphoria, confusion, and in some cases, panic attacks. Due to the high potency and unpredictable effects, the NBOMe series of drugs have been associated with a number of hospitalizations and deaths.

Legal Status

The legal status of 25CN-NBOMe varies by country. In many countries, including the United States, it is a controlled substance. In some countries, it is legal for research purposes but not for human consumption.

See Also

• 25I-NBOMe
• 25B-NBOMe
• 25C-NBOMe
• Psychedelic drug
• Research chemical

References

‎